V
22.70
-7.93 (-25.89%)
| 前收盘价格 | 30.63 |
| 收盘价格 | 21.27 |
| 成交量 | 12,640,762 |
| 平均成交量 (3个月) | 1,570,079 |
| 市值 | 1,447,674,368 |
| 股市价格/股市净资产 (P/B) | 2.71 |
| 52周波幅 | |
| 利润日期 | 6 Aug 2025 - 11 Aug 2025 |
| 稀释每股收益 (EPS TTM) | -3.00 |
| 总债务/股东权益 (D/E MRQ) | 10.18% |
| 流动比率 (MRQ) | 27.68 |
| 营业现金流 (OCF TTM) | -155.26 M |
| 杠杆自由现金流 (LFCF TTM) | -97.14 M |
| 资产报酬率 (ROA TTM) | -23.46% |
| 股东权益报酬率 (ROE TTM) | -39.49% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Vera Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
3.1
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 4.5 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 3.13 |
|
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 5.16% |
| 机构持股比例 | 108.90% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 100.00 (Cantor Fitzgerald, 340.53%) | 购买 |
| 中 | 70.00 (208.37%) | |
| 低 | 26.00 (Wedbush, 14.54%) | 保留 |
| 平均值 | 66.50 (192.95%) | |
| 总计 | 3 购买, 1 保留 | |
| 平均价格@调整类型 | 27.18 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 02 Jun 2025 | 85.00 (274.45%) | 购买 | 31.74 |
| 05 May 2025 | 75.00 (230.40%) | 购买 | 25.53 | |
| Scotiabank | 02 Jun 2025 | 55.00 (142.29%) | 购买 | 31.74 |
| Cantor Fitzgerald | 07 May 2025 | 100.00 (340.53%) | 购买 | 22.62 |
| Wedbush | 07 May 2025 | 26.00 (14.54%) | 保留 | 22.62 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合